FAGR Fagron NV

26.76USD24.40 EUR · EBR-0.61%Mkt Cap: 1.96B USDP/E: 19.52

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compoundi…

Key Statistics

Company
Market Cap1.96B USD
Enterprise Value2.52B USD
Revenue (TTM)1.13B USD
Gross Profit473.82M USD
Net Income (TTM)99.83M USD
Revenue/Share15.40 USD
Last Price26.76 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4.9K
CountryBE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINBE0003874915
Valuation
P/E (Trailing)19.52
P/E (Forward)14.89
PEG15.84
EV/EBITDA13.18
EV/Revenue2.24
P/S1.74
P/B3.01
EPS (TTM)1.37 USD
EPS (Forward)1.80 USD
52W Range
21.9483% of range27.75
52W High27.75 USD
52W Low21.94 USD
Profitability
Gross Margin45.37%
Oper. Margin14.35%
EBITDA Margin16.98%
Profit Margin9.56%
ROE16.50%
ROA7.32%
ROIC13.67%
ROCE14.40%
Growth
Revenue Growth16.00%
Earnings Growth1.60%
Cash Flow & Leverage
Operating CF170.28M USD
CapEx (TTM)33.58M USD
FCF Margin6.54%
FCF Yield3.76%
Net Debt555.46M USD
Net Debt/EBITDA2.90
Net Debt/FCF7.53
Balance Sheet
Debt/Equity0.85
Current Ratio1.77
Quick Ratio1.02
Book Value/Sh8.89 USD
Cash/Share1.96 USD
Dividends
Fwd Div Rate0.44 USD
Trail. Div Rate0.44 USD
Div. Yield1.63%
5Y Avg Yield1.49%
Payout Ratio32.00%
Ex-Div DateMay 18, 2026
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)31.81 USD
Upside (mean)+18.9%
Target Range29.61 USD – 34.00 USD
29.61+18.9% to mean34.00
# Analysts6
Ownership
Shares Out.73.39M
Float65.85M
Insiders0.30%
Institutions71.93%
Technical
SMA 5025.25 (+6.0%)
SMA 20025.34 (+5.6%)
Beta0.32
S&P 52W Chg12.00%
Avg Vol (30d)102.47K
Avg Vol (10d)86.84K
Technical Indicators
RSI (14)60.5
MACD0.3821
MACD Signal0.3920
MACD Hist.-0.0099
BB Upper27.29 USD
BB Middle26.34 USD
BB Lower25.39 USD
BB Width7.20%
ATR (14)0.4461 USD
Vol Ratio (20d)0.65x

About Fagron (EBR: FAGR)

›

Fagron (EBR: FAGR) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 4,880 employees.

The shares were at 24.40 EUR on 19 November 2026, up 19.9% over 52 weeks. Its 52-week range is 20.00 EUR to 25.30 EUR: the price is 3.6% below the high and 22.0% above the low.

At a market capitalisation of 1.79B EUR, it trades at 19.5 times trailing earnings and 14.9 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 21% for FAGR. It pays a dividend yielding 1.63% (it pays out 32% of its earnings), against a median of 1.90% among the dividend payers in that peer group.

Fagron reports return on equity of 16.5%, an operating margin of 14.3% and revenue up 16.0% year over year.

Its debt exceeds its cash by 506.44M EUR, a debt-to-equity ratio of 0.85. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 29.00 EUR is 18.9% above the current price. The next earnings report is expected on 11 February 2027.